Hormone Replacement Therapy: Iron gets in the way

Accumulation of iron with age may inhibit the benefits of hormone replacement therapy on cardiovascular disease in late postmenopause.
  1. Kuldeep Singh
  2. Rajeev Malhotra  Is a corresponding author
  1. Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, United States

Menopause is a biological process often occurring between ages 45 and 55, when egg production ceases and the menstrual cycle ends due to a decline in reproductive hormones, especially estrogen. The postmenopausal state increases the risk of cardiovascular diseases and dying from cardiac-related illnesses, such as a heart attack or stroke. For instance, previous work has shown that compared to age-matched men, premenopausal women are less prone to atherosclerosis, a formation of plaques made up of fatty deposits and other substances inside arteries. However, this protection is lost after menopause, with atherosclerosis progression being particularly prominent in late postmenopausal women over the age of 65 (Moss et al., 2019).

Some studies have suggested that the primary method for treating the symptoms of menopause, hormone replacement therapy (HRT), can also improve cardiovascular health (Herrington et al., 1999; Stampfer and Colditz, 1991). While others have reported HRT to have the opposite effect and actually increase the risk of cardiovascular disease (Hulley et al., 1998; Rossouw et al., 2002). One potential reason for these contradicting results is that HRT benefits cardiovascular health in the early stages of postmenopause but not later on (Boardman et al., 2015; Hlatky et al., 2002; Hodis et al., 2016; Rocca et al., 2014). Now, in eLife, Tong Qiao, Kuanyu Li (both at Nanjing Medical University) and colleagues – including Tianze Xu and Jing Cai as joint first authors – report what could be causing this age-related effect (Xu et al., 2023).

The team (who are based in China, Israel and Mexico) collected plaques and blood samples from atherosclerosis patients who were also postmenopause and divided them into two groups: early postmenopausal (55–65 years old) and late postmenopausal (over 65). They found that samples from the late group contained higher levels of iron and ferritin, the protein that stores iron inside cells. Late postmenopausal patients also produced less of the receptor ERα, which binds to estrogen and is critical for maintaining healthy blood vessels. This suggests that age-related accumulation of iron is negatively associated with ERα levels.

Next, Xu et al. carried out experiments in young mice that had been genetically modified to have atherosclerosis and also had their ovaries removed to trigger the symptoms of menopause. Treating the mice with a form of estrogen known as estradiol, which is used in HRT, increased ERα levels, but only in mice that were early postmenopausal. Conversely, late postmenopausal mice treated with estradiol had less ERα compared to non-treated groups. Thus, it appears that the high levels of iron in the tissues of late postmenopausal mice is somehow impairing the effects of estradiol.

To confirm this effect, Xu et al. conducted further experiments on atherosclerosis mice lacking the gene for ferroportin 1, specifically in their myeloid cells (a type of cell that will mature into certain immune cells of the blood, such as macrophages). The removal of ferroportin 1, a transmembrane protein that exports iron, leads to a buildup of iron inside macrophages. Iron-overloaded macrophages have been shown to speed up the progression of atherosclerosis, whereas macrophages with low levels of iron reduce progression of the disease (Cai et al., 2020; Malhotra et al., 2019). When the mutant mice were treated with estradiol, this resulted in larger atherosclerotic lesions in both the early and late stages of postmenopause. This suggests that iron influences how estradiol impacts atherosclerosis. The mice also had lower levels of ERα in their aortas, which was reduced even further following estradiol treatment.

Xu et al. found that high amounts of iron combined with estradiol downregulated ERα by activating Mdm2, a protein that induces ubiquitin degradation of the estrogen receptor (Figure 1). Reducing the expression of the gene coding for Mdm2 through iron chelation therapy restored ERα levels and attenuated the development of atherosclerosis in late postmenopausal mice.

Schematic representation of the proposed divergent effects of HRT treatment in postmenopause.

If hormone replacement therapy (HRT) is prescribed in the early stages of postmenopause (first 10 years), the estrogen from HRT will slow the progression of atherosclerosis (left; dark blue). Experiments in mice suggest it does this by reducing the levels of Mdm2, an enzyme that signals for the degradation of certain proteins. This results in higher levels of the receptor for estrogen, ERα, which also helps to maintain healthy blood vessels. HRT has the opposite effect when prescribed during the later stages of postmenopause (10 years or more), where it will increase the progression of atherosclerosis (right; light blue). Xu et al. propose that this is due to older individuals having higher levels of iron accumulating in their tissues, which causes estrogen to boost the amount of Mdm2 instead, resulting in lower levels of ERα and increased progression of atherosclerosis.

Overall, this study provides strong evidence that iron accumulation shifts estradiol from a drug that reduces atherosclerosis to a drug that promotes its progression. The excess iron that accumulates in older individuals promotes degradation of ERα, and this is then further amplified by estradiol treatment, counteracting the anti-atherosclerosis effects of the drug. It is important to note that this study does not directly address how HRT and iron affect the stability of atherosclerosis plaques or their chance of rupturing, which is often the cause of a heart attack or stroke.

Previous work has shown that HRT reduces mortality and coronary heart disease, but only if administered in the first 10 years post menopause (Boardman et al., 2015). The study by Xu et al. suggests that this effect may be due to iron accumulating in the blood with age. This highlights the need for clinical studies investigating how iron levels impact the benefits of HRT on cardiovascular health post menopause.


Article and author information

Author details

  1. Kuldeep Singh

    Kuldeep Singh is in the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7187-4782
  2. Rajeev Malhotra

    Rajeev Malhotra is in the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, United States

    For correspondence
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0120-4630

Publication history

  1. Version of Record published: August 10, 2023 (version 1)


© 2023, Singh and Malhotra

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 172
    Page views
  • 10
  • 0

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kuldeep Singh
  2. Rajeev Malhotra
Hormone Replacement Therapy: Iron gets in the way
eLife 12:e90743.

Further reading

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Sevim Kahraman, Kimitaka Shibue ... Rohit N Kulkarni
    Tools and Resources

    Pancreatic a-cells secrete glucagon, an insulin counter-regulatory peptide hormone critical for the maintenance of glucose homeostasis. Investigation of the function of human a-cells remains a challenge due to the lack of cost-effective purification methods to isolate high-quality a-cells from islets. Here, we use the reaction-based probe diacetylated Zinpyr1 (DA-ZP1) to introduce a novel and simple method for enriching live a-cells from dissociated human islet cells with ~ 95% purity. The a-cells, confirmed by sorting and immunostaining for glucagon, were cultured up to 10 days to form a-pseudoislets. The a-pseudoislets could be maintained in culture without significant loss of viability, and responded to glucose challenge by secreting appropriate levels of glucagon. RNA-sequencing analyses (RNA-seq) revealed that expression levels of key a-cell identity genes were sustained in culture while some of the genes such as DLK1, GSN, SMIM24 were altered in a-pseudoislets in a time-dependent manner. In conclusion, we report a method to sort human primary a-cells with high purity that can be used for downstream analyses such as functional and transcriptional studies.

    1. Cell Biology
    2. Physics of Living Systems
    Artur Ruppel, Dennis Wörthmüller ... Martial Balland
    Research Article Updated

    Cell-generated forces play a major role in coordinating the large-scale behavior of cell assemblies, in particular during development, wound healing, and cancer. Mechanical signals propagate faster than biochemical signals, but can have similar effects, especially in epithelial tissues with strong cell–cell adhesion. However, a quantitative description of the transmission chain from force generation in a sender cell, force propagation across cell–cell boundaries, and the concomitant response of receiver cells is missing. For a quantitative analysis of this important situation, here we propose a minimal model system of two epithelial cells on an H-pattern (‘cell doublet’). After optogenetically activating RhoA, a major regulator of cell contractility, in the sender cell, we measure the mechanical response of the receiver cell by traction force and monolayer stress microscopies. In general, we find that the receiver cells show an active response so that the cell doublet forms a coherent unit. However, force propagation and response of the receiver cell also strongly depend on the mechano-structural polarization in the cell assembly, which is controlled by cell–matrix adhesion to the adhesive micropattern. We find that the response of the receiver cell is stronger when the mechano-structural polarization axis is oriented perpendicular to the direction of force propagation, reminiscent of the Poisson effect in passive materials. We finally show that the same effects are at work in small tissues. Our work demonstrates that cellular organization and active mechanical response of a tissue are key to maintain signal strength and lead to the emergence of elasticity, which means that signals are not dissipated like in a viscous system, but can propagate over large distances.